title: Long-term survival of resectable subset after induction chemotherapy in patients with locally advanced head and neck cancer.
abstract: BACKGROUND
  Although meta-analysis showed that survival improved with concurrent chemoradiation in locally advanced head and neck cancer, neoadjuvant chemotherapy is still unique, because it renders curative surgery feasible for marginally resectable head and neck cancer patients.
  
  
  METHODS
  We reviewed patients with locally advanced head and neck cancer, who had been treated with neoadjuvant chemotherapy between June 1984 and February 2001 at the Seoul National University Hospital.
  
  
  RESULTS
  A total of 167 patients were included. After 2 to 3 chemotherapy cycles, either surgery (38 patients) or radiation (104 patients) was conducted. Those who received surgery exhibited better survival than those who received radiation [median survival: not reached vs 33.6 months (95% CI: 22.6-44.7), p = .006]. The 5-year and 10-year survival rates of surgery group were 63.2% and 59.8%.
  
  
  CONCLUSIONS
  The potential benefit of neoadjuvant chemotherapy with surgery in patients with locally advanced head and neck cancers merits further evaluation in future clinical trials.
authors.affiliation: Department of Internal Medicine, Konkuk University Hospital, Konkuk University College of Medicine, Seoul, Korea.
authors.forename: Yo-Han
authors.initials: YH
authors.lastname: Cho
authors.forename: Se Hoon
authors.initials: SH
authors.lastname: Lee
authors.forename: Dong-Wan
authors.initials: DW
authors.lastname: Kim
authors.forename: Hong-Gyun
authors.initials: HG
authors.lastname: Wu
authors.forename: J Hun
authors.initials: JH
authors.lastname: Hah
authors.forename: Chae-Seo
authors.initials: CS
authors.lastname: Rhee
authors.forename: Myung-Whun
authors.initials: MW
authors.lastname: Sung
authors.forename: Kwang Hyun
authors.initials: KH
authors.lastname: Kim
authors.forename: Dae Soeg
authors.initials: DS
authors.lastname: Heo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001761:Bleomycin / Q000008:administration & dosage; D016190:Carboplatin / Q000008:administration & dosage; D002277:Carcinoma / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006258:Head and Neck Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D020360:Neoadjuvant Therapy; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D016019:Survival Analysis; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D016685:Mitomycin; D014750:Vincristine; D005047:Etoposide; D016190:Carboplatin; D002945:Cisplatin; D005472:Fluorouracil